# GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
Canonical URL: https://biopharmsignal.com/news/GOVX/geovax-to-report-second-quarter-2024-financial-results-and-provide-corporate-upd-e5ed0974
Ticker: GOVX
Company: GeoVax Labs
Source: GeoVax Labs
Published: 2024-07-30 13:00 EST
## Summary

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, July 30, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage...

## Article Body
GeoVax to Host Conference Call at 4:30 PM ET

ATLANTA, GA, July 30, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.

Conference Call Details Domestic : (800) 715-9871 International: +1 (646) 307-1963 Conference ID: 3852178 Webcast: https://edge.media-server.com/mmc/p/qj3e68n8

A webcast replay of the call will be available for three months via the same link as the live webcast approximately two hours after the end of the call.

About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com .

| Company Contact: |  | Investor Relations Contact: |  | Media Contact: |
| --- | --- | --- | --- | --- |
| info@geovax.com |  | austin.murtagh@precisionaq.com |  | sr@roberts-communications.com |
| 678-384-7220 |  | 212-698-8696 |  | 202-779-0929 |
## Recent Company News
- 2024-12-09 14:00 EST — [GeoVax Receives Notice of Allowance For Cancer Vaccine Patent](https://biopharmsignal.com/news/GOVX/geovax-receives-notice-of-allowance-for-cancer-vaccine-patent-64188cc4) — Source: GeoVax Labs
- 2024-11-26 14:00 EST — [GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference](https://biopharmsignal.com/news/GOVX/geovax-to-present-at-the-noble-capital-markets-twentieth-annual-emerging-growth--80440681) — Source: GeoVax Labs
- 2024-11-19 14:00 EST — [GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia](https://biopharmsignal.com/news/GOVX/geovax-announces-positive-interim-data-review-for-phase-2-clinical-trial-of-covi-efe6dd0a) — Source: GeoVax Labs
- 2024-11-12 21:00 EST — [GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GOVX/geovax-reports-third-quarter-2024-financial-results-and-provides-business-update-44c641df) — Source: GeoVax Labs
- 2024-11-05 14:00 EST — [GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024](https://biopharmsignal.com/news/GOVX/geovax-to-report-third-quarter-2024-financial-results-and-provide-corporate-upda-37cc2e92) — Source: GeoVax Labs
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)